share_log

Cue Biopharma Analyst Ratings

Cue Biopharma Analyst Ratings

CUE Biophma分析師評級
Benzinga Analyst Ratings ·  2022/11/21 05:08
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/21/2022 117.39% Piper Sandler → $7 Initiates Coverage On → Overweight
08/24/2022 210.56% Oppenheimer $26 → $10 Maintains Outperform
03/21/2022 707.45% Oppenheimer $32 → $26 Maintains Outperform
03/18/2022 707.45% Craig-Hallum $28 → $26 Maintains Buy
11/24/2020 831.68% Berenberg → $30 Initiates Coverage On → Buy
05/20/2020 831.68% Stifel $25 → $30 Maintains Buy
05/20/2020 893.79% Oppenheimer $27 → $32 Maintains Outperform
04/21/2020 676.4% Stifel $21 → $25 Maintains Buy
04/09/2020 552.17% Stifel → $21 Initiates Coverage On → Buy
03/06/2020 831.68% JMP Securities $22 → $30 Maintains Outperform
02/25/2020 738.51% Oppenheimer → $27 Initiates Coverage On → Outperform
01/28/2020 707.45% BTIG → $26 Initiates Coverage On → Buy
01/22/2020 583.23% JMP Securities → $22 Initiates Coverage On → Market Outperform
07/26/2019 303.73% Baird → $13 Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
11/21/2022 117.39% 派珀·桑德勒 → $7 開始承保 →超重
08/24/2022 210.56% 奧本海默 $26 → $10 維護 跑贏大盤
03/21/2022 707.45% 奧本海默 $32 → $26 維護 跑贏大盤
03/18/2022 707.45% 克雷格-哈勒姆 $28 → $26 維護 買
11/24/2020 831.68% 貝倫伯格 → $30 開始承保 →購買
05/20/2020 831.68% Stifel $25 → $30 維護 買
05/20/2020 893.79% 奧本海默 $27 → $32 維護 跑贏大盤
04/21/2020 676.4% Stifel $21 → $25 維護 買
04/09/2020 552.17% Stifel → $21 開始承保 →購買
03/06/2020 831.68% JMP證券 $22 → $30 維護 跑贏大盤
02/25/2020 738.51% 奧本海默 → $27 開始承保 →跑贏大盤
01/28/2020 707.45% BTIG → $26 開始承保 →購買
01/22/2020 583.23% JMP證券 → $22 開始承保 →市場跑贏大盤
07/26/2019 303.73% 貝爾德 → $13 開始承保 →跑贏大盤

What is the target price for Cue Biopharma (CUE)?

Cue Biophma(CUE)的目標價是多少？

The latest price target for Cue Biopharma (NASDAQ: CUE) was reported by Piper Sandler on November 21, 2022. The analyst firm set a price target for $7.00 expecting CUE to rise to within 12 months (a possible 117.39% upside). 4 analyst firms have reported ratings in the last year.

派珀·桑德勒於2022年11月21日報道了Cue Biophma(納斯達克：CUE)的最新目標價。這家分析公司將目標價定為7美元，預計Cue將在12個月內上漲(可能上漲117.39%)。去年有4家分析公司公佈了評級。

What is the most recent analyst rating for Cue Biopharma (CUE)?

Cue Biophma(CUE)的最新分析師評級是多少？

The latest analyst rating for Cue Biopharma (NASDAQ: CUE) was provided by Piper Sandler, and Cue Biopharma initiated their overweight rating.

納斯達克的最新分析師評級是由派珀·桑德勒提供的，Cue Biophma啟動了他們的增持評級。

When is the next analyst rating going to be posted or updated for Cue Biopharma (CUE)?

CUE Biophma(CUE)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cue Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cue Biopharma was filed on November 21, 2022 so you should expect the next rating to be made available sometime around November 21, 2023.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Cue Biophma的高管和客户交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Cue Biophma的上一次評級是在2022年11月21日提交的，所以你應該預計下一次評級將在2023年11月21日左右的某個時候提供。

Is the Analyst Rating Cue Biopharma (CUE) correct?

分析師評級CUE BIOPHMA(CUE)正確嗎？

While ratings are subjective and will change, the latest Cue Biopharma (CUE) rating was a initiated with a price target of $0.00 to $7.00. The current price Cue Biopharma (CUE) is trading at is $3.22, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的Cue Biophma(CUE)評級是以0.00美元至7.00美元的目標價啟動的。Cue Biophma(CUE)目前的交易價格為3.22美元，在分析師的預測區間內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論